Interest Rates Created a Two-Tiered Market. Earnings Will Test It.
Oversold conditions and positive seasonality look promising, but we still need price action to confirm a turn.
Our Small-Cap Name Is Tanking and Nobody Knows Why
Ocular Therapeutix is selling off sharply, taking our small-cap portfolio down with it.
When Will the Key Stocks Start Caring About Bonds?
New lows topped 900 Thursday. That’s a lot. Plus, if my mother calls about interest rates, we’ll have a trifecta.
Amid a Lack of Market Leadership, I’m Eyeing These 2 Stocks
I’m adding to this oil play and biopharma stock as market sees some strange and broad-but-shallow action Tuesday.
Trimming 2 Disappointments, Eyeing 4 Buys
Here’s our trading plan for Friday and updates on key holdings.
Kevin Warsh Puts a Hurting on Our Small-Cap Portfolio
The Federal Reserve chair’s address hurt equities, including several of our names.
A Small-Cap Stock Is Offering an Opportunity — And Almost Nobody Is Covering It
Amid ‘troubling’ market action Monday, here’s what to know about one of my top small-cap plays.
Inseego Reports, and My Question Is: What Was I Thinking?!
Here’s how I’m handling this holding after a dismal report … and why I’m adding to another name that has the right ‘ingredients.’
